INT99187

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 5.07
Pain Relevance 2.99

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (PPARG) enzyme binding (PPARG) DNA binding (PPARG)
lipid metabolic process (PPARG) cytoplasm (PPARG) cytosol (PPARG)
Anatomy Link Frequency
central nervous system 2
PPARG (Homo sapiens)
Pain Link Frequency Relevance Heat
adenocard 1 100.00 Very High Very High Very High
Abeta 4 99.96 Very High Very High Very High
Central nervous system 1 99.96 Very High Very High Very High
cINOD 16 99.44 Very High Very High Very High
COX2 78 98.92 Very High Very High Very High
Inflammation 13 98.80 Very High Very High Very High
agonist 7 97.84 Very High Very High Very High
Analgesic 3 97.34 Very High Very High Very High
Inflammatory mediators 1 89.12 High High
Pain management 1 75.00 Quite High
Disease Link Frequency Relevance Heat
Skin Cancer 65 99.52 Very High Very High Very High
Apoptosis 7 99.24 Very High Very High Very High
INFLAMMATION 18 98.80 Very High Very High Very High
Disease 16 98.64 Very High Very High Very High
Alzheimer's Dementia 7 97.24 Very High Very High Very High
Keratosis 3 86.88 High High
Cancer 47 77.04 Quite High
Malignant Neoplastic Disease 6 76.48 Quite High
Pain 8 75.00 Quite High
Retinoblastoma 2 75.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Future directions for analgesic research are many, but include the use of nitric oxide (NO) NSAIDs; the possibility of decreasing NO in the central nervous system; inhibiting the vanilloid receptor-1; inhibiting adenosine kinase; activating PPARgamma; and mimicking superoxide dismutase, as well as combinations of complementary-acting analgesics.
Negative_regulation (inhibiting) of Positive_regulation (activating) of PPARgamma in central nervous system associated with adenocard, analgesic, cinod and central nervous system
1) Confidence 0.42 Published 2001 Journal Clin. Exp. Rheumatol. Section Abstract Doc Link 11695256 Disease Relevance 0.85 Pain Relevance 1.38
In melanoma, the growth inhibitory effect of PPARgamma activation is independent of apoptosis and seems to occur primarily through induction of cell cycle arrest in the G1 phase of the cell cycle or induction of re-differentiation.
Negative_regulation (effect) of Positive_regulation (activation) of PPARgamma associated with apoptosis and skin cancer
2) Confidence 0.42 Published 2008 Journal Am J Clin Dermatol Section Abstract Doc Link 18092840 Disease Relevance 1.68 Pain Relevance 0.06
Moreover, expression of COX2 was suggested to be regulated by a negative feedback loop involving PPARG and NF-?
Negative_regulation (loop) of Positive_regulation (involving) of PPARG associated with cox2
3) Confidence 0.40 Published 2010 Journal PPAR Research Section Body Doc Link PMC2712952 Disease Relevance 0.63 Pain Relevance 0.43
The pharmacological activity of NSAIDs is generally attributed to inhibition of cyclooxygenase and peroxisome proliferator-activated receptor gamma (PPARgamma) activation.
Negative_regulation (inhibition) of Positive_regulation (activation) of PPARgamma associated with cinod
4) Confidence 0.21 Published 2005 Journal Exp. Neurol. Section Abstract Doc Link 16061222 Disease Relevance 0.65 Pain Relevance 0.38
The activation of PPAR-gamma has been recently reported to reduce Abeta levels in cell culture and AD animal models.
Negative_regulation (reduce) of Positive_regulation (activation) of PPAR-gamma associated with disease and abeta
5) Confidence 0.09 Published 2006 Journal Int. J. Dev. Neurosci. Section Abstract Doc Link 16472958 Disease Relevance 1.26 Pain Relevance 0.74

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox